No Data
No Data
No Data
No Data
No Data
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%
Actinogen Medical (ASX:ACW) completed enrolment of 167 participants in its XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder, according to a Monday fi
MT NewswiresApr 21 21:28 ET
Actinogen Medical Launches Alzheimer's Trial to Test Impact of Xanamem on Cognitive Health
Actinogen Medical (ASX: ACW) has treated the first subject in its clinical trial of patients with biomarker-positive mild to moderate Alzheimer’s disease.
Small CapsApr 14 23:03 ET
Actinogen Doses First Patient in Phase 2b Alzheimer's Disease Trial; Shares Rally 16%
Actinogen Medical (ASX:ACW) dosed the first patient in its phase 2b clinical trial investigating the use of the medication Xanamem in patients with mild to moderate forms of Alzheimer's disease, accor
MT NewswiresApr 14 21:55 ET
Actinogen Medical With Proactive at ASX Small and Mid Cap Conference | ASX:ACW, OTC:ATGGF
Proactive InvestorsMar 27 12:34 ET
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation
Actinogen Medical (ASX:ACW) has notified shareholders that a slide concerning large M&A deals for Karuna Therapeutics and Cerevel Therapeutics in Dec. 2023 incorrectly referred to the deals as lead as
MT NewswiresMar 25 17:22 ET
Investors in Actinogen Medical (ASX:ACW) Have Unfortunately Lost 53% Over the Last Year
Yahoo FinanceMar 12 16:16 ET
No Data
No Data